Cannabis-assisted psychotherapy for complex dissociative posttraumatic stress disorder: A case report

Background: A dissociative subtype of posttraumatic stress disorder, known as “D-PTSD”, has been included in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. In addition to meeting criteria for PTSD, patients endorse prominent dissociative symptoms, namely depersonalization and derealization, or detachment from one's self and surroundings. At present, this population is supported by a highly heterogeneous and undeveloped literature. Targeted interventions are therefore lacking, and those indicated for PTSD are limited by poor efficacy, delayed onset of action, and low patient engagement. Here, we introduce cannabis-assisted psychotherapy (CAP) as a novel treatment for D-PTSD, drawing parallels to psychedelic therapy.

Case presentation: A 28-year-old female presented with complex D-PTSD. In a naturalistic setting, she underwent 10 sessions of CAP, scheduled twice monthly over 5 months, coupled with integrative cognitive behavioral therapy. An autonomic and relational approach to CAP was leveraged, specifically psychedelic somatic interactional psychotherapy. Acute effects included oceanic boundlessness, ego dissolution, and emotional breakthrough. From baseline to post-treatment, the patient showed a 98.5% reduction in pathological dissociation, as measured by the Multidimensional Inventory of Dissociation, no longer meeting criteria for D-PTSD. This was accompanied by decreased cognitive distractibility and emotional suffering, as well as increased psychosocial functioning. Anecdotally, the patient has sustained improvements for over 2 years to date.

Conclusions: There is urgency to identify treatments for D-PTSD. The present case, while inherently limited, underscores the potential of CAP as a therapeutic option, leading to robust and sustained improvement. Subjective effects were comparable to those produced by classic and non-classic psychedelics, such as psilocybin and ketamine. Further research is warranted to explore, establish, and optimize CAP in D-PTSD, and to characterize its role in the pharmacological landscape.

Introduction

Posttraumatic stress disorder (PTSD) is a chronic and disabling psychiatric condition. It has an estimated lifetime prevalence of 7.7% in the United States (1, 2), with a 12-month prevalence rate of 4.1% (1, 3). While presentations vary, PTSD is characterized by thought intrusion, persistent avoidance, negative mood and cognition, and alterations in arousal and reactivity (4). These symptoms are associated with trauma exposure, including sexual, interpersonal, and organized violence, that may accumulate with repeat events over time (5). This leads to considerable psychosocial and occupational disability, with negative downstream effects on quality of life.

Most recently, a dissociative subtype of PTSD, known as “D-PTSD”, has been included in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition [DSM-5; (4)]. Apart from meeting criteria for PTSD, these patients endorse prominent dissociative symptoms, namely depersonalization and derealization, or detachment from one's self and surroundings, as well as emotional disengagement (4, 6). Other complaints include memory disturbance, gaps in awareness, and sensory illusions (7, 8). A recent meta-analysis estimated the prevalence of D-PTSD as 38.1% in patients with PTSD (9). The phenotype is further linked to increased role impairment, psychiatric comorbidity, and suicide risk compared to PTSD alone (10, 11).

To date, only two medications are approved by the Food and Drug Administration for PTSD, sertraline and paroxetine, both of which are selective serotonin reuptake inhibitors (SSRIs). Even when optimally delivered, up to 60% of patients do not respond to SSRIs and <30% achieve remission (12–14). This often results in early medication withdrawal. Moreover, the latency period of these slow-acting antidepressants significantly elevates the risk of suicide and self-injurious behavior (15, 16). As such, trauma-focused psychotherapies are designated as first-line treatments for PTSD, including prolonged exposure (PE) and cognitive processing therapy (CPT) (17). However, these interventions are limited by high attrition rates (>45%) and low patient engagement (18). Novel strategies are therefore urgently needed, especially those targeting dissociative symptoms.

Cannabis, colloquially referred to as “marijuana,” is derived from the Sativa and Indica species of the Cannabis plants (19). It contains cannabinoids and several other chemicals acting on cannabinoid type-1 (CB₁) and type-2 (CB₂) receptors in neurons and immune cells (20). This includes Δ⁹-tetrahydrocannabinol (THC), the main psychoactive ingredient of cannabis known to produce alterations in perception, awareness, and insight; or the “high” commonly reported by users. THC also has analgesic, antiinflammatory, and antioxidant properties (21). In contrast, cannabidiol (CBD) is a non-psychoactive constituent, with anxiolytic, antipsychotic, and anticonvulsive effects (21). Evidence on the clinical benefits of cannabis has thus been growing for a host of indications, ranging from pain to neurologic to sleep disorders (22, 23). There is a particular interest in its application to psychiatric conditions, including PTSD (24). While studies have yet to show robust improvements, their results are confounded by various factors, such as underpowered sample sizes, heterogeneous populations, variant dosing regimens, and anecdotal reporting (25–27). Here, we present the first case, to the best of our knowledge, of cannabis-assisted psychotherapy (CAP) as a treatment for complex D-PTSD, in accordance with CARE (CAse REport) guidelines (28).

Case presentation

A 28-year-old female presented with medical, physical, and sexual polytrauma. At 6 months of age, she was diagnosed with hip dysplasia, resulting in 14 corrective surgeries by age 7. This was compounded by scoliosis and associated chronic pain. The patient was maternally neglected, frequently left without care, adequate food, and supervision. At age 9, she was sexually abused, on multiple occasions, by her mother's boyfriend. This intensified through repeat sexual abuse by a high school partner, persisting until 15 years of age. Overtime, the patient developed a constellation of symptoms, including excessive fear, debilitating anxiety, and negative affect.

According to psychiatric records, she was diagnosed with PTSD plus comorbid anxiety and major depression. The patient first partook in cognitive behavioral therapy (CBT), followed by internal family systems (IFS) therapy and eye movement desensitization and reprocessing (EMDR). These interventions targeted relational trauma, distressing internal experiences, and attachment deficits, respectfully; however, each resulted in poor symptom relief. She was then prescribed various antidepressants, namely sertraline (Zoloft^®), escitalopram (Lexapro^®), and bupropion (Wellbutrin^®). Yet, the patient did not respond to multiple trials of adequate dose and duration. Six years later, she obtained a medical cannabis card to self-manage her chronic pain and PTSD symptoms. This was issued by the Utah Department of Health under the Utah Medical Cannabis Act (House Bill 3001). Despite initial improvement, the patient discontinued use following increased fear and paranoia. Her disease state consequently worsened, leading to agoraphobia and functional disability: “I couldn't leave my house. I couldn't think or clean or make food. I couldn't take care of myself. Everything was too much. Too hard. I was scared all the time, even to use the bathroom at night.” She further reported death anxiety with acute panic attacks: “The thought of dying was overwhelming. It constantly interfered with my daily life.” This decline in mobility and cognition motivated her to re-consider cannabis use, this time with therapy. The patient's prior experience with cannabis, showing signals of improvement in chronic pain and trauma-related symptoms; the market availability and legality of cannabis in the state of Utah; and the accessibility of specialized, clinician-guided services utilizing cannabis, also influenced her decision to seek CAP.

Diagnostic assessment

Upon intake, the patient underwent the Structured Clinical Interview for DSM-5 (SCID-5) (29), confirming complex PTSD. The Multidimensional Inventory of Dissociation (MID) (30), a 218-item multiscale instrument of dissociative phenomena, was also administered. Diagnostic impressions revealed a dissociative subtype, with clinically significant symptoms (cut-off score > 100) present in all three criteria: A (general PTSD dissociative symptoms), B (partially dissociated intrusions), and C (fully dissociated actions). Other complaints included absent-mindedness, inattention, and emotional distress. As such, her clinician recommended repeat CAP, leveraging psychedelic somatic interactional psychotherapy (PSIP) (31). This approach involves autonomic and relational processing, activated by legally prescribed cannabis, to target index trauma. In the patient's case, using PSIP to target core dissociation and interpersonal trauma, stemming from early abandonment, abuse, and enmeshment. Her resistance to first-line treatment for PTSD, including CBT and EMDR, further justified PSIP as an alternative to established, evidence-based psychotherapeutic techniques.

Treatment approach

Akin to psychedelic-assisted therapy [reviewed in (32–34)], CAP included preparation, dosing, and integration. The patient received 10 CAP sessions, scheduled twice monthly over 5 months. This frequency was based on treatment response and tolerability (Figure 1). Sessions were followed by integrative CBT, within 1 week of CAP, aimed at decoding experiential phenomena. The “accept, connect, and embody” (ACE) (35) model, predicated on psychological flexibility, was used to facilitate internal and behavioral change. ACE encourages patients to accept challenging experiences, connect to positive material, and deeply attend somatic cues. See Table 1 for details regarding both CAP and CBT regimens. The setting included a private office with warm lighting, mural tapestries, and live plants. All sessions were video recorded for ethical, safety, and integration purposes.

FIGURE 1

Figure 1. Timeline of clinical events. The patient received 10 CAP sessions, scheduled twice monthly, two-to-three weeks apart, as a treatment for complex D-PTSD. An autonomic and relational approach to psychotherapy was leveraged, namely PSIP. Each CAP session was accompanied by CBT, using the ACE model for integration, to decode experiential phenomena. CBT sessions occurred within 1 week of CAP. ACE, accept, connect, and embody (psychotherapy); CAP, cannabis-assisted psychotherapy; CBT, cognitive behavioral therapy; D-PTSD, dissociative posttraumatic stress disorder; M, month; MID, multidimensional inventory of dissociation; PSIP, psychedelic somatic interactional psychotherapy; S, session; Tx, treatment.

TABLE 1

Table 1. Psychotherapeutic regimens.

Cannabis-assisted psychotherapy

Sessions were primed with psychoeducation and intention setting. The clinician first discussed D-PTSD and its pathogenesis, explained the course of treatment and possible risks, and taught various grounding and self-regulation techniques. Thereafter, the patient developed a clear and positive motive for CAP, designed to help navigate potentially difficult content. Once primed, sessions began with 10–15 min of “surfacing.” Here, thoughts, emotions, and insights from prior CAP sessions were discussed, excluding the first one. This was followed by 10–15 min of “resourcing,” aimed at achieving a present state of calm. This involved clinician-guided exercises, such as deep breathing, positive memory recall, and imaginative thinking. Dosing subsequently occurred. Using a battery-operated vape pen, the patient inhaled 6–10 mg of cannabis chemotype II, a mixed ratio of THC and CBD. Subjective effects included oceanic boundlessness and ego dissolution (Table 2). The clinician then initiated PSIP, targeting dissociative symptoms. Through selective inhibition, the patient suppressed voluntary movement and coping strategies, while fully acknowledging and experiencing urges. This induced hypo- and hyper-arousal, presenting as depersonalization and psychomotor agitation, respectively. Muscle contractions, increased body temperature, and physical discomfort followed. To promote somatic processing, the patient endured the state until sensations abated. This resulted in “traumatic discharge,” breaking emotional and memory blocks, often terminating in psychocatharsis. Sessions closed with 10–15 min of resourcing, with a return to the present moment (Figure 2). The clinician ended by completing a risk assessment to ensure the patient's safety. Acute psychophysiological changes, albeit their intensity, were generally well tolerated and resolved completely. No adverse events were clinically observed nor self-reported.

TABLE 2

Table 2. Subjective effects.

FIGURE 2

Figure 2. Treatment framework. In line with the PSIP model, CAP involved three criteria: surfacing, resourcing, and dosing. Surfacing readied the patient for treatment, integrating experiences from prior sessions, excluding the first one. Resourcing grounded the patient before and after treatment, comprising mindfulness and nervous system regulation. Dosing included cannabis and psychotherapy, as an interactive treatment, targeting dissociative symptoms and interpersonal trauma. CAP, cannabis-assisted psychotherapy; PSIP, psychedelic somatic interactional psychotherapy.

Follow-ups occurred 1 day post-CAP via telephone. Between sessions, the patient watched the previous recording, journaled insights revealed by the experience, and engaged in CBT. This was considered integration work. Her symptoms partially remitted over the first six sessions, and significantly remitted thereon out. From baseline to post-treatment, following all CAP and CBT sessions, the patient showed a 98.5% reduction (RD) in pathological dissociation (M_pre = 19.7 vs. M_post = 0.3), no longer meeting criteria for D-PTSD. This was reflected by robust improvement in 11 clinically significant (cut-off score > 100) dissociative symptoms: derealization (M_pre = 27.5 vs. M_post = 0; RD = 100%), depersonalization (M_pre = 19.2 vs. M_post = 0; RD = 100%), flashbacks (M_pre = 24.2 vs. M_post = 0.8; RD = 96.7%), memory problems (M_pre = 52.5 vs. M_post = 1.7; RD = 96.8%), intrusive impulses (M_pre = 20.0 vs. M_post = 0; RD = 100%), trance (M_pre = 15.8 vs. M_post = 0; RD = 100%), time loss (M_pre = 45.0 vs. M_post = 0; RD = 100%), knowledge loss (M_pre = 26.0 vs. M_post = 0; RD = 100%), child voices (M_pre = 16.7 vs. M_post = 0; RD = 100%), internal voices (M_pre = 33.0 vs. M_post = 0; RD = 100%), and persecutory voices (M_pre = 30.0 vs. M_post = 0; RD = 100%). See Figure 3. She also exhibited marked decreases in cognitive distractibility (M_pre = 62.5 vs. M_post = 3.3; RD = 94.7%) and emotional suffering (M_pre = 47.5 vs. M_post = 2.5; RD = 94.7%), as measured by two response sets, the Cognitive Distraction Scale and Emotional Suffering Scale, both included in the MID.

FIGURE 3

Figure 3. Change in scoring on the MID. From baseline to post-treatment, following all CAP and CBT sessions, the patient showed a robust improvement in clinically significant dissociative symptoms, no longer meeting criteria for D-PTSD. CAP, cannabis-assisted psychotherapy; D-PTSD, dissociative posttraumatic stress disorder; MID, multidimensional inventory of dissociation; RD, reduction.

Collectively, this led to anecdotal improvements in daily life activity, personal development, and overall wellbeing: “I've been able to do things I couldn't do before, like be home alone and with my daughters. I can do stuff around the house and be in public spaces. My fear and anxiety are gone. I don't feel like people are trying to hurt me. I feel more connected with myself and the world. I'm learning to accept my past trauma, without blame and judgment. This is something that changed my life.” She found interactional psychotherapy most beneficial in processing traumatic and relational memory: “I had all this gunk trapped inside that cannabis activated. Engaging with my therapist during sessions helped me resist, fully express, and clear that gunk – painful events I'd been carrying for a long time. I couldn't have done this alone.” The patient also described positive contributions from CBT: “It was extremely helpful to go back and explore my sessions. They were often challenging, but in a good way. Mentally understanding them gave me a lot of clarity and meaning.” Since treatment, the patient has engaged in traditional CBT, as needed, to address her complex trauma history. Remarkably, she has sustained improvements for over 2 years to date. This response was qualitatively described at 8-, 16-, and 24-months follow-up.

Discussion

In this case of complex D-PTSD, CAP showed a striking and sustained reduction in pathological dissociation. This was accompanied by decreased cognitive distractibility and emotional suffering, as well as increased psychosocial functioning. Repeated sessions of CAP, paired with integrative CBT, likely account for the strength and durability of response. Moreover, with gains from CBT for PTSD lasting up to 12 months (36), ad hoc CBT may have prolonged the effects of therapy after treatment, with ongoing development of skills and knowledge overtime.

Notably, the patient described acute changes in oceanic boundlessness, ego-dissolution, and emotional breakthrough. These effects are surprising, given the low dose of cannabis used in each session. If cannabis and psychotherapy act synergistically, with therapy augmenting the response to cannabis, then its combined effect may explain the subjective changes. Irrespective, these facets of mysticism have been reported with high dose cannabis and overlap with those produced by classic psychedelics, including lysergic acid diethylamide (LSD), dimethyltryptamine (DMT), and psilocybin (37–41). They also reflect properties of ketamine, a dissociative agent, known to reduce self-referential awareness and induce feelings of unity, spirituality, and insight (42, 43). These parallels are intriguing, provided distinct mechanisms of action. Cannabis functions as a partial agonist at cannabinoid CB₁ and CB₂ receptors (20), whereas classic psychedelics generally activate serotonin (5–hydroxytryptamine, 5-HT) receptors, particularly 5-HT_2A (44, 45). Ketamine, on the other hand, is a non-competitive antagonist of N-methyl-D-aspartate (NMDA) glutamate receptors, with modulatory effects on neuroplasticity (46).

As psychedelic research on PTSD rapidly expands, the potential of cannabis as a novel pharmacotherapeutic is being questioned (47). This is evidenced by a growing body of literature, systematically reviewed in (27, 48–50). Nabilone, a synthetic cannabinoid that mimics the action of THC, is also being investigated for the condition. The drug shows promise for treating PTSD-related flashbacks and nightmares, with reported improvements in distressing dreams and sleep time (51–54). Notwithstanding, the literature on cannabis in PTSD is highly heterogeneous, stemming from observational and underpowered studies. Its application also remains controversial in humans, with a strong link between trauma and substance dependence (55). The use of adjunctive or combination psychotherapy has neither been explored; and data for D-PTSD is non-existent.

Future research on CAP stands to benefit from the psychedelic “highway,” as a feasible path toward clinical utility (56). This is evermore salient, given similarities between cannabis and psychedelics in public, commercial, and federal interests; the latter reflected by rising state and municipal legalization. Drawing parallels may additionally contribute to paradigm shifts in neuropsychiatry and drug development (57); specifically, looking beyond monoaminergic and glutamatergic systems to an endocannabinoid-based model of chronic stress pathology, aimed at neuromodulation. This may otherwise highlight a patient-specific model of trauma response and recovery.

Psychotherapy must also be considered. As a first-line treatment for PTSD, psychotherapy plays a key role in processing traumatic events, often through re-experiencing. It can also target more distressing ailments, such as guilt and shame, not readily addressed by normalizing neurochemical imbalances. In the present study, cannabis was paired with interactional psychotherapy, namely PSIP, to target complex relational trauma that manifested as fear, negative emotions, and detachment. It was additionally used to support inherent, self-correcting processes that arose during CAP. Learning how psychological interventions, like PSIP, maximize altered states of consciousness will be critical in characterizing mechanisms that lead to favorable outcomes. Hence, it is recommended that CAP be understood in the wider landscape of psychedelic-assisted therapy. For instance, understanding whether CAP is preferentially suited for treating D-PTSD, assuming that all assisted forms of psychedelics are available. A recent cross-sectional study, investigating expectations for CAP, showed comparable beliefs to psilocybin-assisted therapy among two samples of cannabis users (58). Participants believed that CAP, when administered at an ideal dose, could elicit mystical and emotional experiences, as well as alter dysfunctional attitudes. However, more data on CAP is patently needed to establish comparisons, specifically for D-PTSD. Finally, the role of “set and setting” should be examined. As with psychedelics (59), one's mindset and external environment, including the therapist, may interact to shape acute and long-term mental health outcomes.

Limitations

This study has inherent limitations. It describes the history, symptoms, diagnosis, treatment, and follow-up of an individual patient, with no randomization, control, or blinding. Cannabis dosing was also subjectively variable, ranging from 6–10 mg per session. Moreover, it is unclear whether cannabis and psychotherapy were interdependent and necessary, the degree to which each produced clinical benefit, and how effective the treatment would have been with fewer or more sessions. Lastly, a directive, interactional approach to psychotherapy was employed, with an emphasis on autonomic and relational processing. This contrasts to other psychotherapeutic techniques, including cognitive, behavioral, and humanistic therapy. It also differs from gold-standard, evidence-based treatments for PTSD, namely CPT and PE, that are cognitive and exposure-based. Hence, it is premature to generalize the findings of this report. Nonetheless, this study represents the first data on CAP in D-PTSD, within a naturalistic, real-world setting. The results are more robust given the patient's clinical non-response to first- and second-line therapies, the complexity of this population, and its limited evidence base. Larger, well-controlled, and more diverse studies are required to explore potential underlying mechanisms, establish safety profiles and side effects, and assess therapeutic efficacy and effectiveness.

Conclusions

This case highlights the potential of CAP in D-PTSD, with robust and sustained improvement in pathological dissociation. No adverse events were reported. Notably, subjective effects were comparable to those observed in psychedelic therapy, specifically oceanic boundlessness, ego dissolution, and emotional breakthrough. Further data is needed to explore, establish, and optimize CAP in D-PTSD, to determine the contexts and therapeutic frameworks it is best suited for, and to characterize its role in the current pharmacological toolbox.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

Ethics statement

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

MK conceptualized the study and drafted the initial manuscript. AR supervised the work, created all figures, and drafted the final manuscript. MS contributed to the literature review and co-drafted the introduction. CM co-drafted the case presentation. AL co-drafted the results. LJ, AM, and RA contributed to the acquisition of data and critically revised the manuscript for intellectual content. PS, RR, and LA provided field expertise, interpretations of data, and substantial manuscript revisions. All authors have read and approved the final manuscript.

Funding

This work was supported by a Young Investigator Award to MK funded by the Integrated Research Literacy Group (YIA-LG-001-022). LA receives salary support from the U.S. Department of Veterans Affairs (IK2CX001873), and American Foundation for Suicide Prevention (YIG-0-004-16).

Acknowledgments

The authors would like to thank Nicki Wharton, LCSW, the treating clinician on this case, for her collaboration and continued work on CAP. They would also like to acknowledge the patient for courageously sharing her life and treatment experiences.

Conflict of interest

AR is the Founding Director of the Integrated Research Literacy Group. RR serves as Chief Clinical Officer of Numinus Wellness, and is an equity holder in the company. LA serves as a Consultant, Speaker and/or Advisory Board Member for Guidepoint, Transcend Therapeutics, Beond, Source Research Foundation, Reason for Hope, and Ampelis.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Abbreviations

ACE, accept, connect, embody (psychotherapy); CAP, cannabis-assisted psychotherapy; CBD, cannabidiol; CPT, cognitive processing therapy; DMT, dimethyltryptamine; D-PTSD, dissociative posttraumatic stress disorder; DSM-5, diagnostic and statistical manual of mental disorders, fifth edition; MID, multidimensional inventory of dissociation; PE, prolonged exposure; PSIP, psychedelic somatic interactional psychotherapy; PTSD, posttraumatic stress disorder; RD, reduction; SCID-5, structured clinical interview for DSM-5; SSRI, selective serotonin reuptake inhibitors; THC, Δ⁹-tetrahydrocannabinol.

References

1. Goldstein RB, Smith SM, Chou SP, Saha TD, Jung J, Zhang H, et al. The epidemiology of DSM-5 posttraumatic stress disorder in the United States: results from the National Epidemiologic Survey on alcohol and related conditions-III. Soc Psychiatry Psychiatr Epidemiol. (2016) 51:1137–48. doi: 10.1007/s00127-016-1208-5

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Koenen KC, Ratanatharathorn A, Ng L, McLaughlin KA, Bromet EJ, Stein DJ, et al. Posttraumatic stress disorder in the world mental health surveys. Psychol Med. (2017) 47:2260–74. doi: 10.1017/S0033291717000708

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Kessler RC, Chiu WT, Demler O, Walters EE. prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry. (2005) 62:617. doi: 10.1001/archpsyc.62.6.617

PubMed Abstract | CrossRef Full Text | Google Scholar

4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5, 5th Edn. Washington, DC: American Psychiatric Association (2013).

Google Scholar

5. Sareen J. Posttraumatic stress disorder in adults: Epidemiology, pathophysiology, clinical manifestations, course, assessment, and diagnosis. UptoDate. (2019) 1:1.

Google Scholar

6. Schiavone FL, Frewen P, McKinnon M. Lanius RA. The dissociative subtype of PTSD: an update of the literature. PTSD. (2018) 2:3.

Google Scholar

7. Frewen PA, Brown MFD, Steuwe C, Lanius RA. Latent profile analysis and principal axis factoring of the DSM-5 dissociative subtype. Eur J Psychotraumatology. (2015) 6:26406. doi: 10.3402/ejpt.v6.26406

PubMed Abstract | CrossRef Full Text | Google Scholar

8. Mullerová J, Hansen M, Contractor AA, Elhai JD, Armour C. Dissociative features in posttraumatic stress disorder: a latent profile analysis. Psychol Trauma Theory Res Pract Policy. (2016) 8:601–8. doi: 10.1037/tra0000148

PubMed Abstract | CrossRef Full Text | Google Scholar

9. White WF, Burgess A, Dalgleish T, Halligan S, Hiller R, Oxley A, et al. Prevalence of the dissociative subtype of post-traumatic stress disorder: a systematic review and meta-analysis. Psychol Med. (2022) 52:1629–44. doi: 10.1017/S0033291722001647

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Eidhof MB, ter Heide FJJ, van Der Aa N, Schreckenbach M, Schmidt U, Brand BL, et al. The dissociative subtype of PTSD interview (DSP-I): development and psychometric properties. J Trauma Dissoc. (2019) 20:564–81. doi: 10.1080/15299732.2019.1597806

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Lanius RA, Boyd JE, McKinnon MC, Nicholson AA, Frewen P, Vermetten E, et al. A review of the neurobiological basis of trauma-related dissociation and its relation to cannabinoid- and opioid-mediated stress response: a transdiagnostic, translational approach. Curr Psychiatry Rep. (2018) 20:118. doi: 10.1007/s11920-018-0983-y

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Berger W, Mendlowicz MV, Marques-Portella C, Kinrys G, Fontenelle LF, Marmar CR, et al. Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: a systematic review. Prog Neuropsychopharmacol Biol Psychiatry. (2009) 33:169–80. doi: 10.1016/j.pnpbp.2008.12.004

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Ipser J, Seedat S, Stein DJ. Pharmacotherapy for post-traumatic stress disorder - a systematic review and meta-analysis. South Afr Med J Suid-Afr Tydskr Vir Geneeskd. (2006) 96:1088–96. doi: 10.1002/14651858.CD006239

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Stein DJ, Ipser JC, Seedat S, Sager C, Amos T. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst. Rev. (2006) 3:CD002795. doi: 10.1002/14651858.CD002795.pub2

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Jick H. Antidepressants and the risk of suicidal behaviors. JAMA. (2004) 292:338. doi: 10.1001/jama.292.3.338

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry. (2006) 163:41–7. doi: 10.1176/appi.ajp.163.1.41

PubMed Abstract | CrossRef Full Text | Google Scholar

17. Jericho B, Luo A, Berle D. Trauma-focused psychotherapies for post-traumatic stress disorder: a systematic review and network meta-analysis. Acta Psychiatr Scand. (2022) 145:132–55. doi: 10.1111/acps.13366

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Schnurr PP, Chard KM, Ruzek JI, Chow BK, Resick PA, Foa EB, et al. Comparison of prolonged exposure vs cognitive processing therapy for treatment of posttraumatic stress disorder among US veterans: a randomized clinical trial. JAMA Netw Open. (2022) 5:e2136921. doi: 10.1001/jamanetworkopen.2021.36921

PubMed Abstract | CrossRef Full Text | Google Scholar

19. Pertwee RG. Cannabinoid pharmacology: the first 66 years: Cannabinoid pharmacology. Br J Pharmacol. (2006) 147:S163–71. doi: 10.1038/sj.bjp.0706406

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Pertwee RG, Howlett AC, Abood ME, Alexander SPH, Di Marzo V, Elphick MR, et al. International union of basic and clinical pharmacology. LXXIX cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev. (2010) 62:588–631. doi: 10.1124/pr.110.003004

PubMed Abstract | CrossRef Full Text | Google Scholar

21. Brenneisen R. Chemistry and Analysis of Phytocannabinoids and Other Cannabis Constituents in Marijuana and the Cannabinoids. Totowa, NJ: Humana Press (2007).

Google Scholar

22. Choi S, Huang BC. Gamaldo CE. Therapeutic uses of cannabis on sleep disorders and related conditions. J Clin Neurophysiol. (2020) 37:39–49. doi: 10.1097/WNP.0000000000000617

PubMed Abstract | CrossRef Full Text | Google Scholar

23. Levinsohn EA, Hill KP. Clinical uses of cannabis and cannabinoids in the United States. J Neurol Sci. (2020) 411:116717. doi: 10.1016/j.jns.2020.116717

PubMed Abstract | CrossRef Full Text | Google Scholar

24. Sarris J, Sinclair J, Karamacoska D, Davidson M, Firth J. Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review. BMC Psychiatry. (2020) 20:24. doi: 10.1186/s12888-019-2409-8

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Bonn-Miller MO, Sisley S, Riggs P, Yazar-Klosinski B, Wang JB, Loflin MJE, et al. The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: a randomized cross-over clinical trial. PLoS ONE. (2021) 16:e0246990. doi: 10.1371/journal.pone.0246990

PubMed Abstract | CrossRef Full Text | Google Scholar

26. Petersen M, Koller K, Straley C, Reed E. Effect of cannabis use on PTSD treatment outcomes in veterans. Ment Health Clin. (2021) 11:238–42. doi: 10.9740/mhc.2021.07.238

PubMed Abstract | CrossRef Full Text | Google Scholar

27. Stanciu CN, Brunette MF, Teja N, Budney AJ. Evidence for use of cannabinoids in mood disorders, anxiety disorders, and PTSD: a systematic review. Psychiatr Serv. (2021) 72:429–36. doi: 10.1176/appi.ps.202000189

PubMed Abstract | CrossRef Full Text | Google Scholar

28. Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D, et al. The CARE guidelines: consensus-based clinical case reporting guideline development. J Med Case Reports. (2013) 7:223. doi: 10.1186/1752-1947-7-223

PubMed Abstract | CrossRef Full Text | Google Scholar

29. First MB, Williams JB, Karg RS, Spitzer RL. User's Guide for the SCID-5-CV Structured Clinical Interview for DSM-5^® Disorders: Clinical Version. American Psychiatric Publishing, Inc. (2016).

Google Scholar

30. Dell PF. The multidimensional inventory of dissociation (MID): a comprehensive measure of pathological dissociation. J Trauma Dissociation. (2006) 7:77–106. doi: 10.1300/J229v07n02_06

PubMed Abstract | CrossRef Full Text | Google Scholar

31. Razvi S, Elfrink S. The PSIP model an introduction to a novel method of therapy: psychedelic somatic interactional psychotherapy. J Psychedelic Psychother. (2020) 2:3.

Google Scholar

32. Luoma JB, Chwyl C, Bathje GJ, Davis AK, Lancelotta R. A meta-analysis of placebo-controlled trials of psychedelic-assisted therapy. J Psychoactive Drugs. (2020) 52:289–99. doi: 10.1080/02791072.2020.1769878

PubMed Abstract | CrossRef Full Text | Google Scholar

33. Penn A, Dorsen CG, Hope S, Rosa WE, CE. Psychedelic-assisted therapy. AJN Am J Nurs. (2021) 121:34–40. doi: 10.1097/01.NAJ.0000753464.35523.29

PubMed Abstract | CrossRef Full Text | Google Scholar

34. Reiff CM, Richman EE, Nemeroff CB, Carpenter LL, Widge AS, Rodriguez CI, et al. Psychedelics and psychedelic-assisted psychotherapy. Focus. (2021) 19:95–115. doi: 10.1176/appi.focus.19104

PubMed Abstract | CrossRef Full Text | Google Scholar

35. Watts R, Luoma JB. The use of the psychological flexibility model to support psychedelic assisted therapy. J Contextual Behav Sci. (2020) 15:92–102. doi: 10.1016/j.jcbs.2019.12.004

CrossRef Full Text | Google Scholar

36. Van Dis EA, Van Veen SC, Hagenaars MA, Batelaan NM, Bockting CL, Van Den Heuvel RM, et al. Long-term outcomes of cognitive behavioral therapy for anxiety-related disorders: a systematic review and meta-analysis. JAMA Psychiatry. (2020) 77:265–73. doi: 10.1001/jamapsychiatry.2019.3986

PubMed Abstract | CrossRef Full Text | Google Scholar

37. Liechti ME, Dolder PC, Schmid Y. Alterations of consciousness and mystical-type experiences after acute LSD in humans. Psychopharmacology. (2017) 234:1499–510. doi: 10.1007/s00213-016-4453-0

PubMed Abstract | CrossRef Full Text | Google Scholar

38. Barrett FS, Schlienz NJ, Lembeck N, Waqas M, Vandrey R. “Hallucinations” following acute cannabis dosing: a case report and comparison to other hallucinogenic drugs. Cannabis Cannabinoid Res. (2018) 3:85–93. doi: 10.1089/can.2017.0052

PubMed Abstract | CrossRef Full Text | Google Scholar

39. Carbonaro TM, Bradstreet MP, Barrett FS, MacLean KA, Jesse R, Johnson MW, et al. Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. J Psychopharmacol. (2016) 30:1268–78. doi: 10.1177/0269881116662634

PubMed Abstract | CrossRef Full Text | Google Scholar

40. Earleywine M, Ueno LF, Mian MN, Altman BR. Cannabis-induced oceanic boundlessness. J Psychopharmacol Oxf Engl. (2021) 35:841–7. doi: 10.1177/0269881121997099

PubMed Abstract | CrossRef Full Text | Google Scholar

41. Farmer S, Slavin MN, Loflin MJE, Luba R, Earleywine M. Aversiveness and meaningfulness of uncomfortable experiences with edible cannabis. J Psychoactive Drugs. (2019) 51:413–20. doi: 10.1080/02791072.2019.1645371

PubMed Abstract | CrossRef Full Text | Google Scholar

42. Marguilho M, Figueiredo I, Castro-Rodrigues P. A unified model of ketamine's dissociative and psychedelic properties. J. Psychopharmacol. (2022) 17:02698811221140011. doi: 10.1177/02698811221140011

PubMed Abstract | CrossRef Full Text | Google Scholar

43. Sumner RL, Chacko E, McMillan R. A qualitative and quantitative account of patient's experiences of ketamine and its antidepressant properties. J Psychopharmacol. (2021) 35:946–961 doi: 10.1177/0269881121998321

PubMed Abstract | CrossRef Full Text | Google Scholar

44. Belouin SJ, Henningfield JE. Psychedelics: where we are now, why we got here, what we must do. Neuropharmacology. (2018) 142:7–19. doi: 10.1016/j.neuropharm.2018.02.018

PubMed Abstract | CrossRef Full Text | Google Scholar

45. dos Santos RG, Hallak JE, Baker G, Dursun S. Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: evidence and mechanisms of action. J Psychopharmacol. (2021) 35:453–8. doi: 10.1177/0269881120986422

PubMed Abstract | CrossRef Full Text | Google Scholar

46. Aleksandrova LR, Phillips AG. Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. Trends Pharmacol Sci. (2021) 42:929–42. doi: 10.1016/j.tips.2021.08.003

PubMed Abstract | CrossRef Full Text | Google Scholar

47. Legare CA, Raup-Konsavage WM, Vrana KE. Therapeutic Potential of cannabis, cannabidiol, and cannabinoid-based pharmaceuticals. Pharmacology. (2022) 28:1–9. doi: 10.1159/000521683

PubMed Abstract | CrossRef Full Text | Google Scholar

48. Bedard-Gilligan M, Lehinger E, Cornell-Maier S, Holloway A, Zoellner L. Effects of cannabis on PTSD recovery: review of the literature and clinical insights. Curr Addict Rep. (2022) 9:203–16. doi: 10.1007/s40429-022-00414-x

PubMed Abstract | CrossRef Full Text | Google Scholar

49. Orsolini L, Chiappini S, Volpe U, Berardis DD, Latini R, Papanti GD, et al. Use of medicinal cannabis and synthetic cannabinoids in post-traumatic stress disorder (PTSD): a systematic review. Med Kaunas Lith. (2019) 55:E525. doi: 10.3390/medicina55090525

PubMed Abstract | CrossRef Full Text | Google Scholar

50. Rehman Y, Saini A, Huang S, Sood E, Gill R, Yanikomeroglu S, et al. Cannabis in the management of PTSD: a systematic review. AIMS Neurosci. (2021) 8:414–34. doi: 10.3934/Neuroscience.2021022

PubMed Abstract | CrossRef Full Text | Google Scholar

51. Cameron C, Watson D, Robinson J. Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder–related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation. J Clin Psychopharmacol. (2014) 34:559–64. doi: 10.1097/JCP.0000000000000180

PubMed Abstract | CrossRef Full Text | Google Scholar

52. El-Solh AA. Management of nightmares in patients with posttraumatic stress disorder: current perspectives. Nat Sci Sleep. (2018) 10:409–20. doi: 10.2147/NSS.S166089

PubMed Abstract | CrossRef Full Text | Google Scholar

53. Fraser GA. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci Ther. (2009) 15:84–8. doi: 10.1111/j.1755-5949.2008.00071.x

PubMed Abstract | CrossRef Full Text | Google Scholar

54. Jetly R, Heber A, Fraser G, Boisvert D. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology. (2015) 51:585–8. doi: 10.1016/j.psyneuen.2014.11.002

PubMed Abstract | CrossRef Full Text | Google Scholar

55. Cougle JR, Bonn-Miller MO, Vujanovic AA, Zvolensky MJ, Hawkins KA. Posttraumatic stress disorder and cannabis use in a nationally representative sample. Psychol Addict Behav. (2011) 25:554–8. doi: 10.1037/a0023076

PubMed Abstract | CrossRef Full Text | Google Scholar

56. Boehnke KF, Davis AK, McAfee J. Applying Lessons From Cannabis to the Psychedelic Highway: Buckle Up and Build Infrastructure. JAMA Health Forum. (2022) 3:e221618. doi: 10.1001/jamahealthforum.2022.1618

PubMed Abstract | CrossRef Full Text | Google Scholar

57. Averill LA, Abdallah CG. Investigational drugs for assisting psychotherapy for posttraumatic stress disorder (PTSD): emerging approaches and shifting paradigms in the era of psychedelic medicine. Expert Opin Investig Drugs. (2022) 31:133–7. doi: 10.1080/13543784.2022.2035358

PubMed Abstract | CrossRef Full Text | Google Scholar

58. Earleywine M, Mian M, Altman B, De Leo J. Expectancies for cannabis-induced emotional breakthrough, mystical experiences and changes in dysfunctional attitudes: perceptions of the potential for cannabis-assisted psychotherapy for depression. Cannabis. (2022) 5:16–27. doi: 10.26828/cannabis/2022.02.02

CrossRef Full Text | Google Scholar

59. Carhart-Harris RL, Roseman L, Haijen E, Erritzoe D, Watts R, Branchi I, et al. Psychedelics and the essential importance of context. J Psychopharmacol. (2018) 32:725–31. doi: 10.1177/0269881118754710

PubMed Abstract | CrossRef Full Text | Google Scholar